Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Paul E. Hanna MD

Paul E. Hanna MD profile photo picture

Assistant Professor

Institution: Medical College of Wisconsin
Department: Medicine
Division: Nephrology
Program: Administration

image of /images/ORCIDiD_icon16x16.png   https://orcid.org/0000-0003-4976-9104


I am willing to collaborate on research projects.
I am willing to be a peer mentor.

View Curriculum Vitae

Clinical Expertise

  • Acute Kidney Injury
  • Atypical Hemolytic Uremic Syndrome
  • Chronic Kidney Disease-Mineral and Bone Disorder
  • Essential Hypertension
  • Glomerulonephritis
  • Hydronephrosis
  • Hyperparathyroidism, Secondary
  • Hypertension
  • Hypertension, Renal
  • Hypertension, Renovascular
  • Kidney Diseases
  • Kidney Failure, Chronic
  • Kidney Function Tests
  • Kidney Tubular Necrosis, Acute
  • Nephrotic Syndrome
  • Renal Insufficiency
  • Renal Insufficiency, Chronic
  • Tumor Lysis Syndrome

    • Publications (16)

  • Sarcopenia, adiposity and large discordance between cystatin C and creatinine-based estimated glomerular filtration rate in patients with cancer. (Hanna PE, Ouyang T, Tahir I, Katz-Agranov N, Wang Q, Mantz L, Strohbehn I, Moreno D, Harden D, Dinulos JE, Cosar D, Seethapathy H, Gainor JF, Shah SJ, Gupta S, Leaf DE, Fintelmann FJ, Sise ME) J Cachexia Sarcopenia Muscle 2024 Apr 22 PMID: 38646842 SCOPUS ID: 2-s2.0-85191144047 04/22/2024    
  • Risk Factors for Severe Hypertension and Proteinuria after Treatment with Vascular Endothelial Growth Factor Signaling Pathway Inhibitors among Patients with Cancer (Hanna PE, Anumolu RK, Motwani SS, Chen KL, Katz-Agranov N, Green-Lingren O, Yilmam OA, Jhaveri KD, Kitchlu A, Kala J, Sise ME, Gupta S) Kidney International Reports doi: 10.1016/j.ekir.2024.03.005 03/13/2024    
  • Acute and chronic kidney function decline in patients receiving BRAF/MEK inhibitors for melanoma (Mistry K, Zhao S, Strohbehn I, Wang Q, Hanna P, Strohbehn S, Katz-Agranov N, Sullivan RJ, Sise M) Nephrology Dialysis Transplantation doi:10.1093/ndt/gfae049 02/22/2024    
  • Pyelonephritis is an Underrecognized Cause of CKD in Patients With Orthotopic Ileal Neobladder Substitution (Wang Q, Seethapathy R, Ouyang T, Strohbehn IA, Katz-Agranov N, Hanna P, Madken M, Seethapathy H, Gupta S, Heller HM, Wszolek M, Steele D, Klepeis VE, Rennke H, Sise ME) Kidney International Reports December 2023;8(12):2833-2837 SCOPUS ID: 2-s2.0-85173386703 12/01/2023    
  • Adverse kidney outcomes of CDK 4/6 inhibitors for metastatic breast cancer. (Hanna PE, Strohbehn IA, Moreno D, Harden D, Seethapathy R, Sawtell R, Wang Q, Ouyang T, Katz-Agranov N, Dinulos J, Wander SA, Gupta S, Sise ME) NPJ Breast Cancer 2023 Aug 19;9(1):70 PMID: 37598278 PMCID: PMC10439887 SCOPUS ID: 2-s2.0-85168485997 08/20/2023       2 Citations
  • Challenges for optimal care in onconephrology. (Hanna PE, Chowdhury R, Solhjou Z, Gupta S, Jhaveri KD) Nephrol Dial Transplant 2024 Jan 31;39(2):167-169 PMID: 37442629 PMCID: PMC10828197 SCOPUS ID: 2-s2.0-85183980722 07/14/2023    
  • Medication-Related Adverse Events and Discordancies in Cystatin C-Based vs Serum Creatinine-Based Estimated Glomerular Filtration Rate in Patients With Cancer. (Hanna PE, Wang Q, Strohbehn IA, Moreno D, Harden D, Ouyang T, Katz-Agranov N, Seethapathy H, Reynolds KL, Gupta S, Leaf DE, Sise ME) JAMA Netw Open 2023 Jul 03;6(7):e2321715 PMID: 37405775 PMCID: PMC10323710 SCOPUS ID: 2-s2.0-85163940967 07/05/2023       3 Citations
  • Kidney function in patients with ovarian cancer treated with poly (ADP-ribose) polymerase (PARP) inhibitors. (Gupta S, Hanna PE, Ouyang T, Yamada KS, Sawtell R, Wang Q, Katz-Agranov N, Feghali L, Krasner CN, Bouberhan S, Castro CM, Sise ME) J Natl Cancer Inst 2023 Jul 06;115(7):831-837 PMID: 37074956 PMCID: PMC10323894 SCOPUS ID: 2-s2.0-85159271658 04/19/2023       3 Citations
  • Clinical Features of Acute Kidney Injury in the Early Post-Transplantation Period Following Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation. (Vergara-Cadavid J, Johnson PC, Kim HT, Yi A, Sise ME, Leaf DE, Hanna PE, Ho VT, Cutler CS, Antin JH, Gooptu M, Kelkar AH, Wells SL, Nikiforow S, Koreth J, Romee R, Soiffer RJ, Shapiro RM, Gupta S) Transplant Cell Ther 2023 Jul;29(7):455.e1-455.e9 PMID: 37015320 PMCID: PMC10330095 SCOPUS ID: 2-s2.0-85158889828 04/05/2023       1 Citation
  • Oral antiviral therapies for COVID-19 in patients with advanced chronic kidney disease or kidney failure. (Cho WJ, Harden D, Moreno D, Dinulos JE, Hanna PE, Wang Q, Kim AY, Sise ME) Nephrol Dial Transplant 2023 Jul 31;38(8):1912-1914 PMID: 36948600 PMCID: PMC10387392 SCOPUS ID: 2-s2.0-85166383260 03/23/2023       2 Citations
  • Safety of Immune Checkpoint Inhibitors in Patients With Advanced Chronic Kidney Disease: A Retrospective Cohort Study. (Tiu BC, Strohbehn IA, Zhao S, Ouyang T, Hanna P, Wang Q, Gupta S, Leaf DE, Reynolds KL, Sise ME) Oncologist 2023 Jun 02;28(6):e379-e390 PMID: 36821637 PMCID: PMC10243781 SCOPUS ID: 2-s2.0-85162195179 02/24/2023       4 Citations
  • Medication-related adverse events in patients with cancer and discrepancies in cystatin C- versus creatinine-based eGFR. (Hanna PE, Wang Q, Strohbehn I, Moreno D, Harden D, Ouyang T, Katz-Agranov N, Seethapathy H, Reynolds KL, Gupta S, Leaf DE, Sise ME) medRxiv 2023 Jan 18 PMID: 36711583 PMCID: PMC9882433 01/31/2023    
  • Effect of Cancer Stage on Adverse Kidney Outcomes in Patients Receiving Immune Checkpoint Inhibitors for Melanoma (Wang Q, Strohbehn IA, Zhao S, Seethapathy H, Strohbehn SD, Hanna P, Lee M, Fadden R, Sullivan RJ, Boland GM, Reynolds KL, Sise ME) Kidney International Reports November 2022;7(11):2517-2521 SCOPUS ID: 2-s2.0-85139833459 11/01/2022       1 Citation
  • Acute kidney injury in patients receiving pembrolizumab combination therapy versus pembrolizumab monotherapy for advanced lung cancer. (Gupta S, Strohbehn IA, Wang Q, Hanna PE, Seethapathy R, Prosek JM, Herrmann SM, Abudayyeh A, Malik AB, Loew S, Carlos CA, Chang WT, Beckerman P, Mithani Z, Shah CV, Renaghan AD, de Seigneux S, Campedel L, Kitchlu A, Shin DS, Coppock G, Lumlertgul N, Garcia P, Ortiz-Melo DI, Rashidi A, Sprangers B, Aggarwal V, Benesova K, Jhaveri KD, Cortazar FB, Weins A, Zuo Y, Mooradian MJ, Reynolds KL, Leaf DE, Sise ME, ICPi-AKI Consortium) Kidney Int 2022 Oct;102(4):930-935 PMID: 35964800 PMCID: PMC9523226 SCOPUS ID: 2-s2.0-85136628168 08/15/2022       7 Citations
  • Comparison of short- and long-term adverse kidney outcomes after chimeric antigen receptor T cell therapy and autologous hematopoietic stem cell transplant for diffuse large B cell lymphoma. (Hanna P, Strohbehn I, Moreno D, Harden D, Seethapathy H, Gupta S, Lee M, Ouyang T, Frigault M, Sise ME) Bone Marrow Transplant 2022 Oct;57(10):1623-1625 PMID: 35922564 SCOPUS ID: 2-s2.0-85135261848 08/04/2022       2 Citations
  • Acute kidney injury caused by haplostorm after allogenic hematopoietic stem cell transplant. (Hanna P, Strohbehn I, Wang Q, Frigault M, Sise ME) Bone Marrow Transplant 2022 Sep;57(9):1442-1444 PMID: 35661834 SCOPUS ID: 2-s2.0-85131580185 06/07/2022       1 Citation
    • Last update: 04/23/2024